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existing mural thrombus in a well characterized porcine perfusion system in
which a fresh mural thrombus was formed by perfusing severely injured ar-
terial wall with porcine blood for 5 min at a shear rate of 1690ls (correspond-
ing to a moderate coronary stenosis). Thrombus formation was measured
by morphometric analysis. The average mural thrombus achieved in 5 min
was 0.135 mm21mm (n ~ 17).
To quantify the growth of thrombus, MT was perfused with whole blood
of control and treated animals at the same flow conditions.
Thrombus growth on MT was evaluated in pigs treated with Placebo, As-
pirin (ASA, 5 mglkg iv). Heparin IHep, 100 IU/kglh) plus ASA iv, high-dose
Hep (250 IUlkglh ivl, and r-Hirudin (1 mg/kglh ivl as a probe for thrombin. An-
ticoagulation was evaluated by aPIT (sec). Results expressed as thrombus
area (TA mm2lmm, ± SEM) and % growth of thrombus (GT) on MT were
compared by Anova:
Placebo ASA Hep + ASA Hep 250 r-Hir
28 13 6 14 13
TA 0.29 ± 0.01 0.28 ± 0.02 0.20 ± 0.02* 0.15 ± 001* 007 ± 0.01*#1
%GT +119 ± 14 +110± 11 +48 ± 12* +13 ± 5* -48 ± 2*#1
apn 31 ± 3 32 ± 5 46 ± 2 >300 68 ± 3
p < 0.05: * vs Placebo; # vs hep250, 1 vs MT
after initial thrombolysis. We hypothesized that administration of Iys-
plasminogen, which binds to fibrinogen with 10 times greater affinity and
results in a loose fibrin structure (vs native glu-plasminogen) may enhance
the thrombolytic efficacy of t-PA. To examine this hypothesis, dogs with
electrically-induced stable thrombus in the LAD coronary artery were treated
with saline (n = 10) or Iys-plasminogen (2 mg/kg, n = 5) followed 10 minutes
later byt-PA(l mglkg over20 min). Five other dogs with occlusive LAD throm-
bus were first given t-PA followed by Iys-plasminogen (2 mglkg) 40 minutes
later. Blood flow characteristics were observed for 2 hours. Lys-plasminogen
given before t-PA restored flow in all dogs (vs 75% in saline + t-PA group)
in 14 ± 4 minutes (vs 24 ± 3 minutes, P < 0.05) lasting <2 hours (vs 41
± 5 minutes, P < 0.02) with coronary reocclusion rate of 0% (vs 71 %, P
< 0.02). In dogs given Iys-plasminogen after t-PA. the reperfusion rate was
75%, time to reflow 32 ± 6 min, duration of flow 25 ± 19 min and the reoc-
clusion rate 75% (P < 0.05 vs dogs given Iys-plasminogen before t-PA; P-NS
vs dogs given saline + t-PA). Thus recombinant Iys-plasminogen given be-
fore t-PA markedly decreases time to thrombolysis and results in sustained
thrombolysis. In contrast, Iys-plasminogen given after t-PA has no effect on
these parameters of thrombolysis. Enhanced binding of Iys-plasminogen to
fibrinogen in the thrombus resulting in easily dissolvable clot structure may
be the basis of these observations.
These data suggest that by directly inhibiting thrombin activity, r-hirudin
completely inhibits growth of thrombus and is more effective al lower lev-
els of anticoagulation than the highest does of heparin. Specific thrombin
inhibition also leads to an overall reduction of the mural thrombus at shear
rates typical of a moderate coronary stenosis indicating deaggregation of a
pre-existing mural thrombus.
Antiarrhythmic Drug Therapy
Wednesday, March 22,1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 103
Damijan Vokac, Mario Talajic, Tomv Hadjis, Marc Dubuc, Denis RoV, Stanley Natte!.
Montreal Heart Institute, Montreal, Quebec, Canada
In conclusion, Ad causes marked shortening of human atrial action poten-
tial at doses even lower than those used clinically. These effects are rate-
dependent and may account for induction of atrial fibrillation by Ad.
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Administration of adenosine (Ad) frequently terminates reentrant supraven-
tricular tachycardias and may precipitate atrial fibrillation. We characterized
the electrophysiologic effects of incremental doses (1,3,6 mg) of Ad in 8 pts
(age 24-60) during elective electrophysiologic study. Ad was administered
via a central catheter during pacing at cycle lengths (CU of 800, 600 and 500
msec. Monophasic action potentials (MAP) were simultaneously recorded
from the RA and RV and analyzed off-line. Results: Ad decreased atrial MAP
at 90% repolarization (CL 600 msec) by 14, 28 and 35% (1, 3, 6 mg respec-
tively). Ad's atrial effects were rate-dependent (graph A) and dissipated with
a mean time constant of 3.2 ± 0.58 msec (graph BI.
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Studies in rat isolated hearts suggest that adenosine is more potent for slow-
ing antegrade atrioventricular (AV) than retrograde ventriculo-atrial (VA) con-
duction. The potency (EC50) and maximal effect (Emax ) of adenosine to slow
AV and VA conductions were determined in 16 patients (mean age 48 years).
These patients were selected from a group that had a common form of AV
nodal reentrant tachycardia who had prior to the study been subjected to
selective radiofrequency ablation of the slow pathway conduction, but with
intact antegrade and retrograde fast pathway conduction. During high right
atrial and ventricular pacing at comparable cycle lengths (400-500 msec).
adenosine was injected as an intravenous bolus at an initial dose of 0.5 mg
followed by stepwise increase of 1 mg given every 5 minutes until AV or
VA block occurred. The dose-response curves for adenosine-induced pro-
Age (Vr) SMCs MACs T-cells PMNs NC CAL
PR, n = 24 52 ± 10 8% 67% 100% 8% 83% 71%
SU,n = 18 44 ± 7 61% 22% 36% 28% 33% 28%
p-value <0.02 <0.001 <0.01 <0.005 0.12 <0.01 <0.02
SMCs (= smooth muscle cells), MACs I~ macrophages), T-cells, and PMNs (~ neu-
trophils) in plaque adjacent to thrombus: NC = large necrotic core; CAL = calcified plaque
The luminal surface of SU plaques contained accumulations of SMCs
within a proteoglycan matrix. In PR cases, the ruptured fibrous cap was typ-
ically infiltrated by MACs and T-cells. Expression of HLA-DR antigens was
present in MACs and T-cells in 62% of PR cases and expressed in SMCs in
14% of SU cases (p < 0.02). The percent luminal area stenosis was 79 ± 13%
in PR and 71 ± 14% in SU, p < 0.05. No differences in plaque eccentricity
or occlusive vs. non-occlusive thrombi were noted. Conclusions: Superficial
ulceration of smooth muscle cell-rich plaques lacking plaque rupture into a
large necrotic core is a frequent (43%) finding in coronary thrombosis and
is more often seen in younger persons with non-calcified plaques and less
luminal narrowing. The mechanism of coronary artery thrombosis in plaques
rich in SMCs is not mediated by HLA-DR expression and warrants further
study.
Tissue-plasminogen activator (t-PA) activates plasminogen to plasmin which
results in clot lysis. While t-PA administration rapidly restores blood flow
in the thrombosed coronary artery, the coronary artery often reoccludes
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Coronary artery thrombosis (CAT) is reported to occur primarily from plaque
rupture (PRI involving disruption of a fibrous cap over a necrotic core. How-
ever, CAT associated with superficial ulceration ISUI of predominately fi-
bromuscular plaques without rupture of a necrotic core is under-reported.
We performed post-mortem angiography, detailed coronary histology, mor-
phometry, and immunohistochemistry in 42 cases (33 men, 9 women) of
sudden death due to CAT. All individuals died :06 hours of symptom onset.
Histo- and immunochemical stains consisted of Movat pentachrome, H&E,
smooth muscle specific actin, KP-1 (for macrophages). UCHL1 (for T-cells),
Leder stain Ifor neutrophils). and HLA-DR. Results:
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